. Author manuscript; available in PMC: 2020 Aug 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2019 May 11;84(2):447–452. doi: 10.1007/s00280-019-03864-9

Table 1:

Parameter estimates and standard errors for the pharmacokinetic analysis.

		Estimate (%RSE)
Parameters	Parameter Description	Full-plasma PK Study	Microdialysis Studies
		Glioma	Non-tumor mice	Glioma
θ_Ka (1/hr)	First-order absorption constant	2.75 (5.26)	2.75 FIXED	2.75 FIXED
θ_CL (L/hr/kg)	Clearance	2.78 (1.8)	2.78 FIXED	2.78 FIXED
θ_Vc (L/kg)	Volume of central compartment	18.6 (3.87)	18.6 FIXED	18.6 FIXED
θ_CL23 (L/hr/kg)	Influx clearance from plasma to ECF compartment	NE	0.124 (26.8)	0.000000838 (24)
θ_CL32 (L/hr/kg)	Efflux clearance from ECF to plasma compartment	NE	7.78 (8.81)	0.0000808 (11.5)
θ_V3 (L/kg)	Volume of ECF compartment	NE	0.00033 FIXED	0.00033 FIXED
ω_Ka (Exp)	Exponential inter-individual variance in Ka	1.33 (70.3)	0.676 (49.6)	0.712 (42.8)
ω_CL (Exp)	Exponential inter-individual variance in CL	0.0315 (90.6)	0.217 (53.5)	0.0367 (45.4)
ω_CL23 (Exp)	Exponential inter-individual variance in CL23	NE	1.02 (42.7)	0.765 (25.1)
σ_Plasma (Prop)	Proportional residual variance in plasma	0.0277 (7.63)	0.276 (16.1)	0.217 (16.9)
σ_tECF (Prop)	Proportional residual variance in ECF	NE	0.232 (18.4)	0.25 (15.3)
Plasma^* AUC_0–24h		27569 ± 3274	33226 ± 9375^**	28059 ± 3961^***
Plasma^* AUC_0–24h,u		6341 ± 753	7642 ± 2156^**	6454 ± 911^***
Brain/tumor ECF^*			736 ± 610^**	433 ± 451^***
AUC_0–24h
K_p,uu^{^}			0.105 ± 0.085^**	0.065 ± 0.064^***

ng/mL*h;

^**

n=12;

^***

n=16;

^{^}

t-test, p=0.19